Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 4/20 | 0.62 |
| ▸ | ECE1 | P42892 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | LAP3 | P28838 | 3/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43351 | 1.00 | MME (0.62) | MMEECE1MEN1KMT2ALAP3 | |
| SCHEMBL7411127 | 0.92 | MME (0.62) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL7411123 | 0.92 | MME (0.62) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL3098759 | 0.87 | LAP3 (0.56) | MMEECE1MEN1KMT2ALAP3 | |
| SCHEMBL3098754 | 0.87 | LAP3 (0.56) | MMEECE1MEN1KMT2ALAP3 | |
| SCHEMBL2989598 | 0.87 | MME (0.56) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL2996598 | 0.87 | MME (0.56) | MMEECE1MEN1KMT2AACE | |
| SCHEMBL16415834 | 0.86 | MME (0.49) | MMEECE1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7311905 | 0.85 | MME (0.73) | MMEECE1ACE | |
| SCHEMBL2995625 | 0.84 | ANPEP (0.53) | MMEECE1MEN1KMT2AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | UNIV NEW YORK STATE RES FOUND (US) | 2023-11-16 | — | — | US | claimed |
| US-20210205403-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2021-07-08 | — | — | US | claimed |
| US-20200038471-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2020-02-06 | — | — | US | claimed |
| US-20170209521-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-07-27 | — | — | US | claimed |
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2011-07-28 | — | — | US | claimed |
| US-20110034670-A1 | BISUBSTRATE INHIBITORS OF PROTEIN KINASES AS THERAPEUTIC AGENTS | BOARD OF GOVERNORS FOR HIGHER EDUCATION, STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 2011-02-10 | — | — | US | claimed |
| US-7871981-B2 | Inhibition of cell motility, angiogenesis, and metastasis | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-18 | — | — | US | claimed |
| EP-2224961-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | The Research Foundation of the State University of New York (US) | 2010-09-08 | — | — | EP | claimed |
| US-7776844-B2 | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use | YU RUEY J | 2010-08-17 | — | — | US | claimed |
| US-20090208499-A1 | N-(Phosphonoalkyl)-Amino Acids, Derivatives Thereof and Compositions and Methods of Use | YU RUEY J | 2009-08-20 | — | — | US | claimed |
| US-5801149-A | PEPTIDS FOR INHIBITION OF PROTEINS | JOSLIN D-ABETES CENTER, INC. (US) | 1998-09-01 | — | — | US | claimed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | claimed |
| EP-0845217-A1 | Inhibiting undesirable taste in oral compositions | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-03 | — | — | EP | claimed |
| EP-0768821-A1 | pp60PIK : A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | THE JOSLIN DIABETES CENTER, INC. (US) | 1997-04-23 | — | — | EP | claimed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | claimed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | claimed |
| WO-1996032411-A1 | BINDING SITES FOR PHOSPHOTYROSINE BINDING DOMAINS | KAVANAUGH WILLIAM MICHAEL (US) | 1996-10-17 | — | — | WO | claimed |
| WO-1995034201-A1 | pp60PIK: A DOWNSTREAM ELEMENT IN INSULIN SIGNALING | JOSLIN DIABETES CENTER, INC. (US) | 1995-12-21 | — | — | WO | claimed |
| WO-1994008600-A1 | INHIBITION OF SIGNAL TRANSDUCTION MOLECULES | JOSLIN DIABETES CENTER (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1994007913-A1 | PEPTIDE ANTAGONISTS OF SH2 BINDING AND THERAPEUTIC USES THEREOF | WARNER-LAMBERT COMPANY (US) | 1994-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | MME 384/4885ECE1 2587/4885MEN1 715/4885 |
| US-20200038471-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | HMGB2, HMGB1, HMGB3 | MME 384/4885ECE1 2587/4885MEN1 715/4885 |
| US-20170209521-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | HMGB2, HMGB1, HMGB3 | MME 384/4885ECE1 2587/4885MEN1 715/4885 |
| US-20110034670-A1 | BISUBSTRATE INHIBITORS OF PROTEIN KINASES AS THERAPEUTIC AGENTS | SRC, PDXK, DSTYK | MME 845/4885ECE1 3196/4885MEN1 3316/4885 |
| US-20210205403-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | MME 384/4885ECE1 2587/4885MEN1 715/4885 |
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | MME 384/4885ECE1 2587/4885MEN1 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.